CCL22 and primary cutaneous T-cell non-Hodgkin lymphoma: In CTCL, Chang et al. reported that anti-CCR4 antibody significantly suppressed MAC-1 mouse CTCL growth in vivo by inhibiting CCR4/CCL22 pathways and antibody-dependent cellular cytotoxicity activities (22).